Silo Pharma sees growth in IP with the new US patent for a novel ketamine method on stress-induced affective disorders.
Silo Pharma Inc. has received a US patent that covers claims on the use of proprietary ketamine-based drug SPC-15 for the treatment of stress-induced affective disorders, including anxiety and PTSD.
Silo Pharma has an option to license certain assets that are currently being developed by Columbia University, including potential treatments for stress-induced affective disorders and Alzheimer's disease.
SPC-15 is a targeted prophylactic method of treatment and prevention for stress-induced affective disorders, using ketamine compositions as a method of treatment and prevention, working by predicting levels of severity or progression of such disorders and their metabolomic biomarkers response to treatments.
Mindset Pharma gets a Third Family 1 Patent, Expands Composition Of Matter For Psilocybin Analogs
MSSTF has been awarded a new US patent for another Family 1 application, this time covering psilocin derivatives for the treatment of CNS disorders.
The patent, which includes certain deuterated psilocybin analogs, makes up the third of Mindset's Family 1 and is the fourth in terms of the composition of matter IP rights for the company.
See also: This company just created 3 brand new psychedelics - without the hallucinogenic side effects
Family _ 1 consists of psilocybin-inspired drug candidates with improved pharmacokinetic PK efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement in preclinical studies.
Private biotech company Terran Biosciences has published international PCT patent applications covering novel prodrugs based on DMT, 5 MeO-DMT and MDMA.
These applications are based on preclinical data showing that DMT and 5 MeO-DMT can be made orally active through Terran's proprietary prodrug approach, which does not include the traditionally-used monoamine oxidase MAO inhibitor's side effects - nausea, vomiting and changes in blood pressure.
These novel compounds are designed to be used as a single oral dose, avoiding first-pass metabolism, and then breaking down and releasing high levels of the original active molecule DMT in the brain.
Preclinical data shows that the MDMA prodrug holds a significantly longer duration of action than the original psychedelic paired with a reliable pharmacokinetic profile, which could mean the redosing strategy used in MDMA clinical trials would no longer be necessary due to its short-acting effects.
Photo: Benzinga edit with photo by Blue Planet Studio and ANDREI ASKIRKA on Shutterstock.